Friday, 18 Jan 2019

You are here

Mediterranean Diet Reduces Risk of Rheumatoid Arthritis

High adherence to a Mediterranean diet appears to be associated with a lower risk of rheumatoid arthritis (RA), especially in men and those who are seropositive, according to a study published in Arthritis Research & Therapy.

Researchers from the Karolinska Institutet performed a matched, case-controlled study that analyzed the diet of 1,721 patients with incident RA and 3,667 controls. A Mediterranean diet score (0-9) was based on a 124-item food frequency questionnaire.

Overall they found that 24% of RA patients and 28% of controls had high adherence to the Mediterranean diet (score between 6 and 9).

High adherence to a Mediterranean diet reduced the odds of developing RA by 21% (OR 0.79; 95% CI 0.65–0.96) compared to low adherence (score of 0-2).

The RA risk reduction with a Mediterranean diet only applied to men (OR 0.49; 0.33–0.73), and those who were seropositive for rheumatoid factor (RF) (OR 0.69; 95% CI 0.54–0.88) or those with antibodies to citrullinated peptides (ACPA), but not in ACPA-negative RA.  Interestingly, high adherence to a Mediterranean diet did not benefit women (OR 0.94; 95% CI 0.74–1.18), and ACPA or RF-negative RA (OR 0.96; 95% CI 0.68–1.34).

These findings indicate that the Mediterranean diet score was inversely associated with risk of RA, but only in men and those who have seropositive RA. These findings may have implications in those at risk or those deemed to have "pre-clinical RA".

In other studies the Mediterranean diet has been linked with lower risk of mortality, cardiovascular diseases and cancer.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Combo RA Treatment May Boost Risk for Serious Adverse Events

A current meta-analysis of safety and efficacy of combination bDMARD treatment in RA patients shows that combination treatments increase serious advese event (SAE) risks, and the risk for serious infections in particular.

Reassuring VTE Data for Tofacitinib

No significant differences in risk for venous thromboembolism (VTE) were seen in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) and those receiving tumor necrosis factor (TNF) inhibitors, analysis of administrative data showed.

CV Risks Similar in Systemic Sclerosis and Rheumatoid Arthritis

Interactions between disease-related inflammatory processes and the development of several morbidities have been well-studied in RA, particularly heart disease. This is not the case for the often-lethal SSc (estimated standardized mortality ratio between 2.5 and 4.0). Similarly, there are no studies comparing the most relevant comorbidities between SSc and RA.

PRAIRI Study - Can RA Be Prevented?

B-cell depletion may offer a means of delaying the onset of clinical arthritis in adults at high risk, according to the PRAIRI study - a proof-of-mechanism study in pre-clinical RA patients. 

Rheumatoid Lung Disease Imposes Significant Morbidity and Mortality

Insurance claims data were analyzed for the frequency of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA) and finds that although rare, its frequency increased over time and it is associated with a significant mortality rate. 

The study was done because RA-ILD has been shown to cause significant morbidity and mortality.